Carnival vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Miami global cruise (NYSE: CCL) at record $25B FY2024 revenue (+15%), EBITDA $6.1B (+40%); 90+ ships 9 brands, 2025 guidance ~20% earnings growth, "nearly 2/3 booked at all-time pricing" competing with Royal Caribbean.
About
Carnival Corporation & plc is a Miami, Florida-based global cruise company — publicly traded on both the New York Stock Exchange (NYSE: CCL) and the London Stock Exchange (LSE: CCL) as an S&P 500 Consumer Discretionary component — operating the world's largest fleet of cruise ships across nine distinct cruise brands serving North American, European, and Australian vacationers: Carnival Cruise Line, Princess Cruises, Holland America Line, Seabourn, Costa Cruises, AIDA Cruises, P&O Cruises (UK), P&O Cruises (Australia), and Cunard, through approximately 160,000 employees and 90+ ships calling on 700+ ports in all seven continents. In fiscal year 2024 (ending August 2024), Carnival achieved record total revenues of $25 billion (+15% year-over-year), net income of $1.9 billion, and record adjusted EBITDA of $6.1 billion (+40%) — with management guiding approximately 20% earnings growth for 2025, supported by nearly two-thirds of the year already booked at all-time high pricing and occupancy levels at the time of guidance. CEO Josh Weinstein, who assumed leadership in 2022, has led the company's post-COVID financial recovery from the industry's most severe disruption — a 15-month fleet shutdown (March 2020 to June 2021) that required Carnival to raise $30+ billion in emergency debt and equity capital — toward the current record performance cycle.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.